Peel Hunt Keeps The Buy Rating They’ve had for PureTech Health Plc (LON:PRTC) Shares

June 19, 2018 - By Darrin Black

PureTech Health plc (LON:PRTC) Logo

PureTech Health Plc (LON:PRTC) Rating Reaffirmed

In a research note revealed to investors on Tuesday, 19 June, Peel Hunt reiterated their Buy rating on PureTech Health Plc (LON:PRTC) shares.

PureTech Health plc (LON:PRTC) Ratings Coverage

Among 5 analysts covering PureTech Health Plc (LON:PRTC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. PureTech Health Plc has GBX 313 highest and GBX 245 lowest target. GBX 266.25’s average target is 68.51% above currents GBX 158 stock price. PureTech Health Plc had 17 analyst reports since January 2, 2018 according to SRatingsIntel. On Monday, January 29 the stock rating was maintained by Numis Securities with “Buy”. Peel Hunt maintained PureTech Health plc (LON:PRTC) rating on Friday, January 26. Peel Hunt has “Buy” rating and GBX 313 target. The rating was maintained by Peel Hunt on Wednesday, April 4 with “Buy”. Liberum Capital maintained the shares of PRTC in report on Friday, January 26 with “Buy” rating. The company was maintained on Thursday, February 1 by Peel Hunt. The firm has “Buy” rating by Numis Securities given on Tuesday, February 20. The firm has “Buy” rating given on Thursday, March 1 by Peel Hunt. The rating was maintained by Peel Hunt on Tuesday, February 20 with “Buy”. The firm has “Buy” rating given on Tuesday, June 19 by Peel Hunt. The firm has “Buy” rating by Liberum Capital given on Thursday, March 1.

The stock increased 3.95% or GBX 6 during the last trading session, reaching GBX 158. About 18,063 shares traded. PureTech Health plc (LON:PRTC) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company has market cap of 446.24 million GBP. The firm is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It has a 12.15 P/E ratio. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: